Buy CHINA Up to $2.50 per Share

With a strong track record in consolidation and organic growth of its software business, we believe CDC Corporation (CHINA - Snapshot Report) is poised for growth.

The company's Q4 2008 results were hurt by impairment charges and a decline in software revenue. With continuous focus on vertical industries and cost reduction initiatives in its software segment, CDC should develop a significant competitive advantage in 2009 and beyond.

New launches and upgrades (Yulgang 3.0 and Ross Enterprise v6.3.2) in its product line as well as its integration efforts will further help the company drive growth. As such, we maintain our Buy rating on the shares of CDC with a six-month target price of $2.50.

Priyanka Poddar contributed to this report.